regulus therapeutics inc (RGLS) Key Developments
Regulus Therapeutics Inc. Presents at BMO Capital Markets Biotech Corporate Access Day, Jul-30-2015
Jul 23 15
Regulus Therapeutics Inc. Presents at BMO Capital Markets Biotech Corporate Access Day, Jul-30-2015 . Venue: Boston, Massachusetts, United States.
Regulus Therapeutics Inc. Initiates Phase I Clinical Study of RG-012
Jun 4 15
Regulus Therapeutics Inc. announced that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ('miR-21'). RG-012 is being developed by Regulus in a strategic alliance with Genzyme for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. The Phase I clinical study is being conducted in the United States as a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of subcutaneous dosing of RG-012 in healthy volunteers. In addition to the Phase I clinical study, Regulus is currently enrolling Alport syndrome patients in a natural history of disease study called ATHENA. With this study, which has thirteen clinical sites worldwide, Regulus aims to learn more about the changes in renal function over time in patients with Alport syndrome. Data from the ATHENA study will provide the clinical basis for the design of a Phase II study to monitor the therapeutic effect of RG-012 on the decline in renal function and time to end-stage renal disease in Alport syndrome patients. In addition, Regulus expects that many patients enrolled in ATHENA will be eligible to enroll in a Phase II proof-of-concept study, which Regulus expects to initiate under its 'Clinical Map Initiative' following the conclusion of the Phase I clinical study.
Regulus Therapeutics Inc. Announces Management Changes
Jun 1 15
Regulus Therapeutics Inc. announced that Kleanthis G. Xanthopoulos, Ph.D. has resigned as President and Chief Executive Officer and as a member of the company’s Board of Directors, effective June 1, 2015, to pursue investment opportunities in the biotechnology industry. Paul Grint, M.D., who previously served as Chief Medical Officer, has been appointed as President and Chief Executive Officer and as a member of Board of Directors effective June 1, 2015. In addition, Neil W. Gibson, Ph.D., who has served as Chief Scientific Officer, will continue through June 30, 2015 at the company as President's Fellow to assist Dr. Grint in assembling a new leadership team.
Regulus Therapeutics Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015
May 7 15
Regulus Therapeutics Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, revenues under strategic alliances and collaborations were $4,200,000 against $1,631,000 a year ago. Loss from operations was $12,871,000 against $10,705,000 a year ago. Loss before income taxes was $14,491,000 against $12,740,000 a year ago. Net loss was $14,487,000 against $12,741,000 a year ago. Basic and diluted net loss per share was $0.29 against $0.30 a year ago. Net loss in the first quarter 2015 included approximately $1.8 million in non-cash charges associated with amended and restated convertible promissory note compared to approximately $2.1 million in the same period in 2014. Revenue for the first quarter 2015 was highlighted by the achievement of a $2.5 million preclinical milestone upon AstraZeneca's selection of RG-125 as a clinical candidate.
Regulus Therapeutics Inc., Annual General Meeting, Jun 10, 2015
Apr 30 15
Regulus Therapeutics Inc., Annual General Meeting, Jun 10, 2015., at 09:00 Pacific Standard Time. Location: 3545 John Hopkins Court. Agenda: To elect the seven nominees for director named herein to serve until the next annual meeting and their successors are duly elected and qualified; to ratify the selection by the audit committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending 2015; and to conduct any other business properly brought before the meeting.